Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Nephrology"
DOI: 10.1038/nrneph.2017.140
Abstract: New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as… read more here.
Keywords: nephropathy renoprotective; renoprotective effects; glp1r agonists; effects glp1r ... See more keywords
812-P: The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-812-p
Abstract: GLP-1 agonists and SGLT2 inhibitors are increasingly prescribed as second line agents for type 2 diabetes. However, costs for these drugs are high. Pharmaceutical manufacturers often cite high development costs as a justification for high… read more here.
Keywords: industry; nih academia; agonists sglt2; glp agonists ... See more keywords